Incidence and time course of adverse events (AEs) with atezolizumab (A) in combination with vemurafenib (V) and cobimetinib (C) in the phase III IMspire150 study
No Thumbnail Available
Identifiers
Date
2020-09-01
Authors
Lewis, K.
Robert, C.
Ascierto, P. A.
Munhoz, R.
Liszkay, G.
de la Cruz Merino, L.
Olah, J.
Queirolo, P.
Mackiewicz, J.
Li, H.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
